Company: NCEL
Filing Date: 2025-11-06
Form Type: POS AM
Source: 0001213900-25-106799
Chunk: 5

Company: NewcelX Ltd.
Filing Date: 2025-11-06
Form: POS AM
Chunk 5
---
 the interim report contain forward -looking statements based upon current expectations that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward -looking statements as a result of several factors, including but not limited to those set forth under Item 3.D. “Risk Factors” in our Annual Report on Form 20 -F for the year ended December 31, 2024, or the Annual Report, on file with the SEC. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Certain information included herein may be deemed to be “forward -lookingstatements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward -lookingstatements are often characterized by the use of forward -lookingterminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “project” or other similar words, but are not the only way these statements are identified. Forward -lookingstatements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward -lookingstatements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward -lookingstatements include, but are not limited to, statements about: •the ability of NLS and Kadimastem to consummate the Merger; •the risks that the consummation of the Merger is substantially delayed or does not occur, for example due to the failure to obtain shareholder approval; •the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; •the expected benefits of the Merger; •the unexpected costs related to the proposed Merger; •the financial and business performance of NLS, including financial projections and business metrics and any underlying assumptions thereunder; •changes in NLS’s and Kadimastem’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; •the implementation, market acceptance and success of NLS’s and Kadimastem’s business model; •NLS’s and Kadimastem’s ability to scale in a cost -effectivemanner; •developments and projections relating to NLS’s and Kad